Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD In this Article Evobrutinib shows efficacy up to 108 weeks in open-label extension study Government study evaluating Rebif® (interferon beta-1a) as COVID-19 treatment Stem cell therapy for MS: Examining the impact on cognition The primary factor shaping patients’ treatment choices Why taking your disease-modifying therapy […]

Updated September 3, 2020 Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD On August 20, 2020, Novartis announced that the United States Food and Drug Administration (FDA) approved Kesimpta® (ofatumumab) for adults with relapsing forms of multiple sclerosis (RMS), which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary-progressive disease. Kesimpta is a […]

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD On August 17, 2020, the United States Food and Drug Administration (FDA) awarded early approval of Mylan’s generic version of Biogen’s Tecfidera® (dimethyl fumarate), an oral medication approved in 2013 for relapsing forms of MS in adults. Mylan announced the launch of this generic medication […]

In an effort to provide accurate and easily accessible information about the ongoing COVID-19 pandemic, the Multiple Sclerosis Association of America (MSAA) and Wondros are proud to announce the creation of the COVID-19 and MS Pathfinder online tool, available on MSAA’s website at https://mymsaa.org/covid-19-and-ms-pathfinder/. The COVID-19 and MS Pathfinder tool allows members of the multiple […]

The Multiple Sclerosis Association of America advocates equally for all members of the MS community, and supports all peaceful efforts aimed at erasing the inequalities that exist between people of different races, religions, gender, and economic backgrounds, as well as those with disabilities. MSAA recognizes the inequities and overwhelming pain associated with discrimination and senseless acts of injustice.

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD The commercial launch and availability of Zeposia® (ozanimod) for the treatment of adults with relapsing forms of multiple sclerosis (RMS) was officially announced today. Initially approved by the United States Food and Drug Administration (FDA) on March 25, 2020, the makers of Zeposia, Bristol Myers Squibb, […]

Challenges presented by the COVID-19 pandemic can be even more stressful and overwhelming for people living with chronic illnesses. As a trusted resource for the multiple sclerosis (MS) community, the Multiple Sclerosis Association of America (MSAA) is committed to providing accurate, up-to-date information, and resources during this time. Webinars about COVID-19 and Multiple Sclerosis Streamed […]

On April 30, 2020, Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, announced the United States Food and Drug Administration (FDA) approval of Bafiertam™ (monomethyl fumarate) delayed-release oral capsules to treat relapsing forms of multiple sclerosis (MS). This approval includes the treatment of clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary-progressive MS (SPMS). Banner has not yet announced when the medication will be available to the MS community.

Reviewed by MSAA Chief Medical Officer Barry A. Hendin, MD Overview On March 26, 2020, Bristol Myers Squibb announced that the United States Food and Drug Administration (FDA) approved Zeposia® (ozanimod) for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary-progressive MS […]